Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trial.
Goga A, Ramraj T, Naidoo L, Daniels B, Matlou M, Chetty T, Dassaye R, Ngandu NK, Galli L, Reddy T, Seocharan I, Ndlangamandla Q, September Q, Ngcobo N, Reddy M, Cafun-Naidoo T, Woeber K, Jeenarain N, Imamdin R, Maharajh K, Ramjeth A, Bhengu T, Clarence E, Van de Perre P, Tylleskär T, Nagot N, Moles JP, Moore PL, Mkhize NN, Gama L, Dispinseri S, Biswas P, Scarlatti G; PedMAb1 clinical trial team.
Goga A, et al. Among authors: van de perre p.
BMC Infect Dis. 2024 Jul 20;24(1):712. doi: 10.1186/s12879-024-09588-3.
BMC Infect Dis. 2024.
PMID: 39033300
Free PMC article.